Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Research and Innovation Action · Running

TiilT Preclinical development of a 3rd-generation interleukin-2 targeted to inflammatory sites

Coordinator
Sorbonne Universite, France
Runs
1 June 2023 to 31 May 2028
Status
Running
EU funding
€5.6m
Total cost
€5.6m
Partners
10 organisations in 6 countries
Type
Research and Innovation Action
Grant agreement
101080897

What the project is doing

In the project's own words, from its summary on CORDIS.

As major players in the regulation of immune responses, regulatory T cells (Tregs) are important therapeutic targets for autoimmune and inflammatory diseases. Interleukin-2 (IL-2) used at low doses (IL-2LD) stimulate and expand Tregs in vivo. While 1st-generation native IL-2LD are currently under extensive clinical evaluation, pharmaceutical companies are developing 2nd-generation IL-2 muteins with improved half-life and activity.

We aim to develop 3rd-generation IL-2 specifically targeting inflammatory sites (IL-2IT) by using antibodies (Abs) against oxidation specific epitopes (OSE) that are both universal markers and mediators of inflammation. IL-2-OSE-Ab fusion proteins should allow dampening of local inflammation by a double-hit mechanism involving Ab neutralization of pro-inflammatory OSE and IL-2 stimulation of Tregs. As a proof of concept, we designed a first IL-2IT in which an IL-2N88R mutein is fused to an scFv from a prototypic anti-OSE Ab.

This IL-2IT (i) binds to IL-2 receptors and OSE, (ii) has an extended half-life and (iii) superior therapeutic efficacy compared to native IL-2 in mice. Our general objectives are to design an optimized IL-2IT by testing combinations of different anti-OSE Ab with IL-2 and IL-2 muteins, and to complete its preclinical development in mice and macaques. We will validate the use of IL-2IT in cardiovascular diseases (CVD), i.e. atherosclerosis, vasculitis, myocardial infarction and SLE-associated CVD, as these conditions have been shown to be improved by Treg infusions, native IL-2 and OSE-Abs in mice.

Carried by leading experts in the use IL-2, OSE-Abs, models of CVD, and clinical trials with native IL-2, the successful validation of an IL-2IT will open a new era for highly selective and effective immunotherapies based on Treg stimulation for diseases that represent a leading cause of death and morbidity. Furthermore, it will validate the broader concept of targeting any therapeutic molecule to inflammatory sites.

Topics

Who is involved

OrganisationCityCountryRole
Sorbonne UniversiteParisFranceCoordinator
Medizinische Universitaet WienWienAustriaParticipant
Universitaet Zu LuebeckLubeckGermanyThird party
Universitatsklinikum Schleswig-HolsteinLübeckGermanyParticipant
Icosagen Cell Factory OuKambja ValdEstoniaParticipant
Commissariat a L Energie Atomique Et Aux Energies AlternativesParisFranceParticipant
Iltoo PharmaParisFranceParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Universita Degli Studi Di TriesteTriesteItalyParticipant
King's College LondonLondonUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI